Efanesoctocog Alfa Prophylaxis Beneficial for Children With Hemophilia A

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, July 19, 2024 -- For children with severe hemophilia A, once-weekly prophylaxis with efanesoctocog alfa is associated with high sustained factor VIII activity, resulting in effective prevention of bleeding, according to a study published in the July 18 issue of the New England Journal of Medicine.

Lynn Malec, M.D., from the Versiti Blood Research Institute in Milwaukee, Wisconsin, and colleagues conducted a phase 3, open-label study involving 74 previously treated male patients younger than 12 years of age with severe hemophilia A who received 52 weeks of prophylaxis with once-weekly efanesoctocog alfa (50 IU/kg).

The researchers found that no factor VIII inhibitors developed and most of the adverse events were nonserious. There were no reports of serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa. Seventy-three patients were treated according to the protocol and had median and model-based mean annualized bleeding rates of 0.00 and 0.61, respectively. Overall, 64, 88, and 82 percent of patients had no treated bleeding episodes, no spontaneous bleeding episodes, and no episodes of bleeding into joints, respectively. Ninety-five percent of the 43 bleeding episodes resolved with one injection of efanesoctocog alfa. Mean factor VIII activity at steady state was >40 IU/dL and >10 IU/dL for three and almost seven days after dose administration, respectively. The investigators observed a 40.0-hour geometric mean terminal half-life.

"Once-weekly efanesoctocog alfa (50 IU per kilogram) provided high sustained factor VIII activity and highly efficacious protection against bleeding episodes in children with severe hemophilia A, a population in which this goal has been difficult to achieve without burdensome treatment regimens," the authors write.

The study was funded by Sanofi and Sobi, the development partners for efanesoctocog alfa.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-20 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords